Intersect ENT   Report issue

For profit Phase 3
Founded: Menlo Park CA United States (2003)
Status: Acquired by Medtronic (2021)

Organization Overview

First Clinical Trial
2013
NCT01732536
First Marketed Drug
2017
mometasone (elocon)
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Intersect ENT | INTERSECT ENT INC

Active Ingredients

Marketed Drugs (1)

mometasone (elocon) (2017)

Drugs in Phase 3 Trials (1)

mometasone (elocon) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chronic Disease (Phase 3)

Nasal Polyps (Phase 3)

Polyps (Phase 3)

Sinusitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1